Analyzing Repro-Med Systems (OTCMKTS:REPR) and DexCom (OTCMKTS:DXCM)
Repro-Med Systems (OTCMKTS:REPR) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.
This table compares Repro-Med Systems and DexCom’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Repro-Med Systems and DexCom’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Repro-Med Systems||$17.35 million||7.04||$910,000.00||N/A||N/A|
|DexCom||$1.03 billion||15.31||-$127.10 million||$0.30||577.30|
Repro-Med Systems has higher earnings, but lower revenue than DexCom.
Institutional and Insider Ownership
17.8% of Repro-Med Systems shares are held by institutional investors. Comparatively, 94.2% of DexCom shares are held by institutional investors. 40.0% of Repro-Med Systems shares are held by company insiders. Comparatively, 0.9% of DexCom shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
Repro-Med Systems has a beta of -0.32, indicating that its stock price is 132% less volatile than the S&P 500. Comparatively, DexCom has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.
This is a breakdown of current recommendations for Repro-Med Systems and DexCom, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
DexCom has a consensus price target of $167.00, indicating a potential downside of 3.57%. Given DexCom’s higher probable upside, analysts clearly believe DexCom is more favorable than Repro-Med Systems.
DexCom beats Repro-Med Systems on 7 of the 12 factors compared between the two stocks.
Repro-Med Systems Company Profile
Repro Med Systems, Inc., doing business as RMS Medical Products, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and RMS precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was founded in 1980 and is headquartered in Chester, New York.
DexCom Company Profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Receive News & Ratings for Repro-Med Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repro-Med Systems and related companies with MarketBeat.com's FREE daily email newsletter.